CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.68
+0.03 (+1.82%)
As of 12:20PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.65
Open1.65
Bid1.67 x 800
Ask1.69 x 900
Day's Range1.61 - 1.70
52 Week Range1.36 - 8.70
Volume127,792
Avg. Volume302,498
Market Cap55.744M
Beta0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.34
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.67
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Report: Developing Opportunities within Q2, Ormat Technologies, The Andersons, Comstock Resources, Freshpet, and Curis — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Q2 ...

  • PR Newswire22 days ago

    Curis to Present at the Baird 2018 Global Healthcare Conference

    LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York. The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session. A live webcast of the presentation will be available by visiting the investors section of Curis' website http://investors.curis.com/events-and-presentations.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 36.59% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Curis: 2Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 26 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • PR Newswire2 months ago

    Curis Reports Second Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire2 months ago

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

    LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications

    NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...

  • Investopedia2 months ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • PR Newswire2 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., July 9, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on July 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 12,000 shares of Curis common stock to a new employee, with a grant date of July 2, 2018 (the "Q3 2018 Inducement Grant"). Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.  Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.  CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.  CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...

  • ACCESSWIRE4 months ago

    Curis Shares Show Recent Gains, Pipeline Review and FDA Decision

    NEW YORK, NY / ACCESSWIRE / June 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Curis, Inc. (CRIS) is a biotechnology company, focused on the development and commercialization of drug candidates for the treatment of human cancers. Curis announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018. Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opened on Wednesday, May 30, 2018.

  • Why Curis, Inc. Is Soaring Today
    Motley Fool4 months ago

    Why Curis, Inc. Is Soaring Today

    Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.

  • PR Newswire4 months ago

    /C O R R E C T I O N -- Curis, Inc./

    In the news release, Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, issued 31-May-2018 by Curis, ...

  • PR Newswire4 months ago

    Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 29, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018.  Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on Wednesday, May 30, 2018.  The new CUSIP number for Curis's common stock following the reverse stock split is 231269 200. The reverse stock split affects all issued and outstanding shares of Curis's common stock, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans.  The reverse stock split will reduce the number of shares of the Curis's issued and outstanding common stock from approximately 337,500,000 million to approximately 67,500,000 million.  In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options outstanding immediately prior to the reverse stock split, with a proportional increase in exercise price.  The reverse stock split will proportionately reduce the number of authorized shares of common stock.

  • PR Newswire4 months ago

    Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

    LEXINGTON, Mass., May 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development. In this newly created role, Dr. Martell, a practicing oncologist and experienced drug developer, will directly manage the day-to-day operations of the Curis clinical development and research efforts. Dr. Martell is a member of the Board of Directors of Curis, and will resign from his board duties simultaneous with his start date on June 1st.

  • PR Newswire4 months ago

    Curis Announces 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 22, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its Board of Directors approved a 1-for-5 reverse split of Curis's common stock that is expected to take effect on Tuesday, May 29, 2018 after the close of trading. The reverse stock split will affect all holders of common stock uniformly and will not alter any stockholder's percentage ownership interest in Curis, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.

  • Investopedia4 months ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CRIS earnings conference call or presentation 3-May-18 12:30pm GMT

    Q1 2018 Curis Inc Earnings Call

  • Associated Press5 months ago

    Curis: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 7 cents per share. The drug developer posted revenue of $2.5 million in the period. The company's shares closed at 56 cents. A year ago, ...

  • PR Newswire5 months ago

    Curis Reports First Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire5 months ago

    Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018

    LEXINGTON, Mass., April 26, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.

  • Are Earnings Prospects Improving For Loss-Making Curis Inc’s (NASDAQ:CRIS)?
    Simply Wall St.5 months ago

    Are Earnings Prospects Improving For Loss-Making Curis Inc’s (NASDAQ:CRIS)?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Curis Inc’s (NASDAQ:CRIS) track record on a highRead More...